Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.68 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19219079 | 0.96 | PDPK1 (0.63) | PDPK1LOXL2CYP2A6ADRB2MAPT | |
| SCHEMBL722198 | 0.87 | PDPK1 (0.77) | PDPK1LOXL2CYP2A6ADRB2SMPD3 | |
| Acetic Acid SCHEMBL5456096 | 0.87 | PDPK1 (0.58) | PDPK1LOXL2CYP2A6ADRB2MAPT | |
| SCHEMBL30060874 | 0.82 | PDPK1 (0.58) | PDPK1LOXL2CYP2A6ADRB2MAPT | |
| Acetic Acid Methyl Ester SCHEMBL5461039 | 0.82 | PDPK1 (0.49) | PDPK1LOXL2CYP2A6ADRB2SMPD3 | |
| 2-Phenylthiazole SCHEMBL70646 | 0.81 | PDPK1 (1.00) | PDPK1LOXL2CYP2A6ADRB2LMNA | |
| Water SCHEMBL27772406 | 0.80 | PDPK1 (0.61) | PDPK1LOXL2CYP2A6ADRB2SMPD3 | |
| SCHEMBL31351160 | 0.80 | PDPK1 (0.45) | PDPK1LOXL2CYP2A6ADRB2MAPT | |
| 2-Phenylthiazole SCHEMBL4939218 | 0.79 | PDPK1 (0.95) | PDPK1LOXL2CYP2A6ADRB2LMNA | |
| SCHEMBL17704291 | 0.79 | PDPK1 (0.65) | PDPK1LOXL2CYP2A6ADRB2SMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102863435-A | 2-[[4-fluoro-3-(trifluoromethyl) phenyl] amino]-4-pyridyl-5-thiazole formaldehyde and preparation method of reduction product thereof | YANCHENG INST TECHNOLOGY | 2013-01-09 | — | — | CN | claimed |
| WO-2011049274-A1 | IMIDAZOLE DERIVATIVES AND COMPOSITIONS FOR TREATING MELANOMA | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-04-28 | — | — | WO | claimed |
| EP-0680967-B1 | Erythromycin derivatives, their process of preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (FR) | 1998-10-14 | — | — | EP | claimed |
| WO-1995029929-A1 | NOVEL ERYTHROMYCIN DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE AS DRUGS | ROUSSEL UCLAF (FR) | 1995-11-09 | — | — | WO | claimed |
| EP-0680967-A1 | Erythromycin derivatives, their process of preparation and their use as medicaments | ROUSSEL-UCLAF (FR) | 1995-11-08 | — | — | EP | claimed |
| JP-59016889-A | — | — | None | — | — | JP | disclosed |
| CN-108383858-B | Derivatives of imidazothiadiazoles and imidazopyrazines for the treatment of platelet aggregation | 百时美施贵宝公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20220332712-A1 | HETEROARYL-PYRIDINIUM COMPOUND AND REDOX FLOW BATTERY COMPRISING THE SAME | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2022-10-20 | — | — | US | disclosed |
| CN-111205456-B | Macrocyclic compound, preparation method and application thereof | 中国科学院上海高等研究院 | 2022-07-05 | — | — | CN | disclosed |
| CN-108373476-B | Kinase inhibitor and preparation and application thereof | 成都地奥制药集团有限公司 | 2021-06-01 | — | — | CN | disclosed |
| EP-3215142-B1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2021-03-24 | — | — | EP | disclosed |
| CN-110981891-B | Methanol fluorescent probe based on viologen derivative, preparation method and application | 郑州大学 | 2020-10-30 | — | — | CN | disclosed |
| EP-0097323-A3 | 2-(4-PYRIDYL)-THIAZOLE DERIVATIVES | SCHERING CORPORATION (US) | 1985-08-07 | — | — | EP | disclosed |
| EP-0097323-A3 | 2-(4-PYRIDYL)-THIAZOLE DERIVATIVES | SCHERING CORPORATION (US) | 1985-08-07 | — | — | EP | disclosed |
| US-4528291-A | 2-(4'-Pyridinyl)-thiazole compounds and their use in increasing cardiac contractility | SCHERING CORPORATION (US) | 1985-07-09 | — | — | US | disclosed |
| US-4528291-A | 2-(4'-Pyridinyl)-thiazole compounds and their use in increasing cardiac contractility | SCHERING CORPORATION (US) | 1985-07-09 | — | — | US | disclosed |
| JP-S5916889-A | 2-(4-PYRIDYL)-THIAZOLE DERIVATIVE | SCHERING PLOUGH CORP | 1984-01-28 | — | — | JP | disclosed |
| EP-0097323-A2 | 2-(4-Pyridyl)-thiazole derivatives | SCHERING CORPORATION (US) | 1984-01-04 | — | — | EP | disclosed |
| EP-0097323-A2 | 2-(4-Pyridyl)-thiazole derivatives | SCHERING CORPORATION (US) | 1984-01-04 | — | — | EP | disclosed |
| EP-0097323-A2 | 2-(4-Pyridyl)-thiazole derivatives | SCHERING CORPORATION (US) | 1984-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332712-A1 | HETEROARYL-PYRIDINIUM COMPOUND AND REDOX FLOW BATTERY COMPRISING THE SAME | NOX4, DUOX1, PNPO | PDPK1 926/4885LOXL2 488/4885CYP2A6 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.